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Abstract
Sleep apnea syndromes are characterized by repeated episodes of breathing
pauses (apnea) or significant reductions in respiratory amplitude (hypopnea)
during the patient’s sleep. These episodes significantly alter the sleep struc-
ture of the patient and provoke acute cardiorespiratory responses that may
be deleterious in the long term. Continuous positive airway pressure (CPAP)
therapy is the gold-standard treatment for SAS, but patient compliance to
this therapy is low. This paper presents a new system for real-time detection,
monitoring and treatment of SAS, based on triggered kinesthetic stimulation.
The system is composed of 3 components: i) a cardio-respiratory recorder,
ii) a kinesthetic stimulator and iii) a real-time processing application, inte-
grating an ”on-off” control method to trigger the kinesthetic stimulation as
a function respiratory event detections. A preliminary evaluation of the sys-
tem, performed on 46 patients suffering from severe SAS is also presented.
This evaluation is focused on i) the performance characterization of the real-
time respiratory event detector and ii) a qualitative description of the effect of
the therapy. A satisfactory real-time respiratory event detection performance
(sensitivity= 89.2%, positive predictive value = 59%) was obtained with the
proposed detector, when evaluated retrospectively using the acquired data.
Three case reports, describing the cardiorespiratory response to the ther-
apy of a responder, a partially-responder and a non-responder patients are
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also presented. These preliminary results are very encouraging and warrant
further developments, in particular for novel control stimulation strategies.
Keywords: Sleep apnea syndrome, kinesthetic stimulation, closed-loop
therapy
1. Introduction
Sleep apnea syndrome (SAS) is a multifactorial disease characterized by
repeated episodes of breathing pauses (apnea) or significant reductions in
respiratory amplitude (hypopnea) during the patient’s sleep. SAS concerns
more than 5% of the general population, but it is still under-diagnosed [1, 2].
This is particularly true in populations considered ”at risk”, such as those
suffering from cardiovascular diseases and type 2 diabetes, where the presence
of SAS increases the risk of complications [3, 4, 5]. In these populations, in
particular, the prevalence of SAS is estimated to be greater than 50%[6].
Patients suffering from SAS show apnea or hypopnea episodes that can
be repeated from 5 to 100 times per hour of sleep, with durations ranging
from 10 seconds to several minutes, strongly affecting the sleep structure of
the patient. The ”apnea hypopnea index” (AHI), calculated as the number
of apnea and hypopnea events per hour, is a key clinical marker to quan-
tify the severity of apnea in a given patient. The gold-standard for SAS
diagnosis is polysomnography (PSG), which requires manual scoring of all
events by a trained specialist. Consequently, SAS remains highly under-
dianosed due to long waiting-lists in sleep laboratories. There is therefore
the need for new reliable automatic diagnostic strategies for improving the
detection and management of patients suffering from SAS [7]. Diagnostic
systems should include more advanced data processing methods, able to bet-
ter exploit the complementary information acquired from different cardio-
respiratory signals. Regarding therapy, the gold-standard treatment is by
continuous positive airway pressure (CPAP). The CPAP machine delivers a
continuous stream of compressed air via a nose or full-face mask. This posi-
tive pressure keeps the airway open and prevents it from collapsing, so that
unobstructed breathing becomes possible [8]. However, patient compliance is
low, with 15% initial refusal and low adherence in the long term for 20-30%
of them [9]. Therefore, new therapeutic solutions are also needed.
This paper describes the first version of a new system for the detection,
monitoring and treatment of SAS, directed to improve patient management
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by integrating both a real-time diagnostic approach and a better treatment
tolerance that may improve long-term observance. This system has been
developed within the framework of the ANR TecSan project entitled ”Per-
sonalized and Adaptive kinesthetic StImulation Therapy, based on cardio-
respiratory Holter monitoring, for slEep Apnea syndromes” (PASITHEA),
supported by the French ”Agence Nationale pour la Recherche”. Prelimi-
nary results from the first clinical evaluation (HYPNOS study) of the system
will be presented and discussed.
2. System description
The PASITHEA system is composed of three main components (Fig. 1):
1. a cardiorespiratory ambulatory recorder (Holter), providing data ac-
quisition and wireless transmission of the acquired data in real time;
2. a kinesthetic stimulation system, comprising a stimulation signal gen-
erator and a kinesthetic actuator, typically positioned behind the ear;
3. a control device for adaptive kinesthetic stimulation which will be em-
bedded, in a first phase, into a computer.
These three components interact using a specific wireless communication
protocol, based on the Bluetooth (BT) technology. Eight complete systems
were built and tested. The following subsections describe each of the main
modules of the system in more details.
2.1. Cardiorespiratory Holter
A commercially available Sorin Holter system was modified by partner
SORIN CRM in order to meet the requirements of the project. The new car-
diorespiratory Holter prototype is capable of acquiring and locally recording
two ECG channels (sampling frequency: 256 Hz, resolution: 10 µV, fre-
quency response: 0.05-80 Hz), nasal pressure (sampling frequency: 256 Hz)
and blood oxygen saturation (SaO2) (sampling frequency: 1 Hz) during a
whole night. This system can also transfer these data in real-time (every 100
ms) through a BlueTooth Low Energy (BTLE) link towards the real-time
signal processing application for further processing.
2.2. Kinesthetic stimulation system
The kinesthetic stimulation system has been developed by partner LTSI,
based on previous prototypes already used for kinesthetic stimulation therapy
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Figure 1: General diagram of the PASITHEA system showing its main components: 1) the
cardio-respiratory Holter, 2) kinesthetic stimulator and 3) the real-time application for
data processing and control.
Figure 2: The prototype cardiorespiratory Holter device with associated sensors (ECG
electrodes, SaO2 ear sensor and nasal pressure cannula).
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for apnea-bradycardia on preterm newborns [10]. The system consists in a
command module (Figure 3a) and a kinesthetic actuator (Figure 3b).
The command module is a battery-operated device that can generate
dynamic stimulation signals in an adaptive fashion. This module is based
on an ATmega168 micro-controller, embedding a custom, multi-agent soft-
ware that handles all the functionalities of the device. In particular, the
micro-controller can synthesize sinus signals with varying amplitudes and
frequencies, to be presented as input to a driver circuit that will handle the
kinesthetic effector. The command module can function either in an ”au-
tonomous” or a ”slave” mode. The slave mode requires establishing a BT
connection with a master system (in this case, the real-time control applica-
tion) that will command the operation of the stimulator.
The stimulating device is a resonant linear actuator with optimal reso-
nance frequency of 175Hz (model C10-100, Precision Microdrives Ltd, Lon-
don, UK). At 100% of the acceptable input signal amplitude (2V RMS), this
actuator generates a typical normalized acceleration of 13.7 m/s2.
Figure 3: The kinesthetic stimulation system, showing (a) an opened control module and
(b) and the kinesthetic actuator.
2.3. Real-time processing and control application
This application, depicted in figure 4, is in charge of: i) establishing
wireless communication links with the Holter and the stimulator, ii) receiv-
ing data from the cardio-respiratory Holter, iii) performing real-time signal
processing on the received signals for the detection of apnea or hypopnea
episodes and iv) according to the detector’s output, apply the proposed ”on-
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off” controller and send the appropriate command to the kinesthetic stimu-
lator through a BT link.
	
Figure 4: Real-time application for data acquisition, processing and control. Left panel:
user-defined configuration parameters and BT connexion with the Holter and the stimu-
lator. Central panel: 4 screens showing real-time acquired data: 2 ECG channels (top),
nasal pressure (bottom left), SaO2 (bottom right). Right panel: Output of the real-time
respiratory event detector (apnea or hypopnea) and stimulation parameters.
2.3.1. Wireless communications and data acquisition:
The control application establishes wireless BT links with the Holter and
the stimulator device and performs device initialization and management us-
ing specifically developed application-level communication protocols. Meth-
ods of error correction and verification of the integrity of the BT links have
been integrated into the protocol and are also handled by the control appli-
cation. Data acquisition is initiated and terminated by the application and
all available signals are received in real-time from the Holter at their original
sampling rates.
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2.3.2. Real-time respiratory event detector
The respiratory event detector is based on the segmentation of respiratory
cycles from the acquired nasal pressure signal. A full respiratory cycle is
defined as inhalation followed by exhalation. Inhalation is detected when the
nasal pressure signal exceeds a positive threshold value (λI(t)). Exhalation
is detected when nasal pressure signal falls below a negative threshold value
(λE(t)). Thresholds λI(t) and λE(t) are updated independently, through
time, according to the patient’s breathing patterns. An apnea is detected as
the absence of inhalation for more than δa ∈ [3, ..., 10] seconds. A hypopnea
event is detected when inhalation amplitude falls below 50% below inhalation
baseline for more than δh ∈ [5, ..., 10] seconds. A complete description, as
well as a prospective evaluation of this method can be found on a recent
publication [11]. In this paper, we propose an improvement of this detector,
integrating the following modifications:
• an additional criterion was required for apnea detection: an apnea was
detected not only as the absence of inhalation for a certain time but
also as a ”flat” breathing line, i.e. nasal pressure amplitude had to stay
within the inhalation and exhalation thresholds
• the time to detect apneas (δa) was not a fixed parameter but would
be set, within limits, as the average of the patient’s latest respiratory
cycle periods.
• the time to detect hypopnea (δh) was not a fixed parameter but linked
to the amplitude of inhalation drop: a quicker detection for severe
hypopnea (with a large drop) and a slower detection for less severe
hypopnea
A retrospective assessment of this improved version (referred to as v2) is
given in Table 1. However, it is to note that the output of the original version
of the detector has been used as control variable for triggering kinesthetic
stimulation for the patients included in the Hypnos study.
2.3.3. Control of the kinesthetic stimulation
In this first version of the PASITHEA system a real-time ”on-off” control
method is implemented into the application, using as control variable the
detector’s output. When respiratory event detection is confirmed, around
8 seconds after the beginning of the respiratory event, a command is sent
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to the kinesthetic stimulator to activate it. Although the system is able to
apply different stimulation strategies for different types of respiratory events
[12, 13], the following unique stimulation strategy was used in this paper:
A constant amplitude is applied to the patient at a frequency of 175 Hz.
Kinesthetic stimulation is organized into bursts of a maximum duration of
3 s each, followed by a silent period of 2 s. A maximum of 3 bursts are
applied in a given detected respiratory event. This burst-based stimulation
is applied in order to minimize patient habituation to the stimulation as well
as the fragmentation of the patient’s sleep. When the detector confirms the
end of the respiratory event (first detected deflection on the nasal pressure
signal above a given threshold during a respiratory event) a command is sent
to stop kinesthetic stimulation.
3. System evaluation methodology
Evaluation of this first version of the PASITHEA system has started
within the framework of a clinical protocol approved by the ethics committee
of the Grenoble University Hospital (HYPNOS study), and involving five
centers: the University Hospitals of Angers, Grenoble, Montpellier, Rennes
and Tours. The first objective of this study is to validate the on-line real-time
methods for the detection and characterization of apnea and hypopnea during
sleep, taking the polysomnography (PSG) as a gold standard. A secondary
objective of this study is to obtain preliminary results on the effect of the
proposed on-off controlled kinesthetic stimulation on respiratory events.
3.1. Data acquisition and patient population
After signing an informed consent, all patients underwent a full PSG
in a sleep laboratory. Nasal pressure (NP), electrocardiography (ECG) and
oxygen saturation (SaO2) were simultaneously acquired and processed by the
PASITHEA system. Using a T-deviation tube, the same nasal pressure was
presented as input to the sensors of both the cardiorespiratory Holter and the
PSG systems. Central reading of PSG was performed by an expert, blinded
core-lab (CHU Grenoble, France) who provided the overall AHI together with
an accurate scoring of individual events (start, duration and type of event)
for each patient.
A total of 46 severe obstructive sleep apnea (OSA) patients (mean age:
58.5, BMI: 30.1 kg/m2, AHI: 47.7 /h - with 92% of obstructive events, 75%
male) were included in this study. 12 patients were included in a titration
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phase, dedicated to optimize the parameters of the respiratory event detector
and to establish the amplitude of the kinesthetic bursts that were used for the
rest of the study. 34 additional patients were included on the study phase,
with a fixed stimulation amplitude of 80% of the maximum power of the
stimulator (normalized acceleration of approx. 11 m/s2). This stimulation
amplitude value was determined during the titration phase. 4 patients were
totally excluded from the analysis due to problems with the PSG recording,
or to a bad nasal cannula signal, preventing correct detection of respiratory
events. Additionally, 4 other patients are excluded from the therapy analysis
because the stimulation therapy was not delivered (failure of the stimulator
cable or connector), but they can participate in the analysis of the detec-
tion performance. In total, 30 patients are thus available for the analysis of
detection performance and 26 patients are available for the analysis of the
therapy.
3.2. Evaluation of the respiratory event detector
Regarding the evaluation of the detector’s performance, a training set
constituted of the first 12 patients included in the study was used for the
definition of the detector parameters. At the end of this phase, the pa-
rameters were fixed to δa = 8 seconds for the apneas and δh = 10 seconds
for hypopnea (see section above). A test set composed of the remaining 30
patients was used to assess the detector performance. Performance was as-
sessed by matching PSG annotated events (blinded core-lab scoring) with
the PASITHEA detector output. A true positive (TP) event was defined as
an event detected less than 10 seconds before or within the duration of a
PSG-annotated event. Note that for a global assessment of respiratory event
detection, apneas detected as hypopneas (and reciprocally) were regarded as
true positives. Delay to the detection was defined as the time lag between
the detector output and the start of the event, as per core-lab PSG annota-
tion. The detector sensitivity (SE) and positive predictive value (PPV) were
calculated as usual:
SE(%) = TP/(TP + FN) · 100 (1)
PPV (%) = TP/(TP + FP ) · 100 (2)
where FN and FP represent respectively the number of false negative and
false positive detections. The 95% confidence intervals of the detector outputs
were calculated using the Wilson score.
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3.3. Preliminary evaluation of the cardiorespiratory response to the therapy
For this preliminary evaluation, each patient represented its own refer-
ence, by defining successive periods during which the simulator was active
(stim-on) or inactive (stim-off ). The first hour of the recording was per-
formed without any stimulation in order to let the patient fall asleep. The
rest of the recording was divided into consecutive segments of 30 minutes in
stim-on and 30 min of stim-off.
A qualitative patient-by-patient analysis of the obtained cardiorespiratory
responses to the kinesthetic therapy was performed, with the objective of
evaluating if a given patient correctly responds to the kinesthetic stimulation.
A correct response has been defined as a return to normal breathing, during
or immediately after the delivery of kinesthetic stimulation. The absence of
a return to normal breathing after the end of the third stimulation burst was
considered as a no-response. A partial response was defined when the patient
intermittently showed a correct or a no-response to the therapy throughout
the night. Preliminary results shown in this paper will consist on three case-
reports regarding the cardiorespiratory response observed from i) a responder
patient, ii) a partially-responder patient and iii) a non-responder patient.
4. Results
4.1. Evaluation of the apnea/hypopnea detector
The global performance of the real-time apnea/hypopnea detector is given
in Table 1. Only the stim-off periods were included in the analysis, to
avoid any bias of potential events interrupted by kinesthetic stimulation.
Overall, 2561 apneas and 1679 hypopneas were scored on the PSG. 3656
events were correctly detected within the 10-second window (see definition
of a true positive above). 2367 false positive events were detected, among
which 318 apneas and 697 hypopnea were wrongly detected while the patient
was awake. Breathing baseline fluctuations due to movements during awake
periods explain the high number of wrongly detected hypopneas, while nasal
cannula withdrawal and physiological apneas at sleep onset (that are not
scored on the PSG since they are not pathological) account for most of the
false positive apneas during wakefulness. The use of a sleep detector, that
would temporarily turn off the real-time event detection while the patient is
awake, would significantly improve the PPV (second line of Table 1).
Apnea and hypopnea events were always detected well before the con-
ventional 10 seconds requirement to define a respiratory event, with a mean
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delay of 6.0 seconds and 8.7 seconds for apneas and hypopneas respectively.
The second version of the detector (v2), when tested retrospectively on the
test set significantly reduced this detection delay (down to 4.1 seconds for
apneas and 3.5 seconds for hypopneas on average) while sensitivity slightly
improved and PPV remained similar.
Table 1: Real-time respiratory event detector performances. Values are given as mean [95%
Confidence intervals]. The first two lines give the performances of the on-line detector,
as assessed prospectively on all 30 patients included in the evaluation phase of the study.
The last line gives the performances of the improved detector (v2) on the same patients,
but assessed retrospectively.
Analysis
method
SE(%) PPV(%) Apnea
detection
delay (sec)
Hypopnea
detection
delay (sec)
Prospective 86.2 60.7 6.0 8.7
Event-based [85.2-87.2] [59.5-61.9]
Prospective 86.2 78.3 6.0 8.7
Event-based [85.2-87.2] [77.1-79.4]
Asleep only
Retrospective (v2) 89.2 59.0 4.1 3.5
Event-based [88.4-89.8] [58.1-59.9]
4.2. Qualitative preliminary responses of the kinesthetic stimulator
This section will present three case reports, describing the cardiorespira-
tory response to the proposed triggered kinesthetic therapy of a responder
patient, a partially responder patient and a non-responder patient.
4.2.1. Responder patient
Figure 5 shows the cardio-respiratory effect of the therapy on one respon-
der patient, using the PASITHEA system v1. The first 10 min in this figure
correspond to a stim-off segment and the following 10 min correspond to
a stim-on phase. The nasal pressure (NP) signal shown in the upper panel
(Fig. 5-A) was applied as input to the above-mentioned respiratory event
detector.
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Figure 5-B shows the stimulation signal (Stim), obtained as output from
the on-off controller, used to activate the kinesthetic actuator. Note that, as
expected, no stimulation is performed during the stim-off phase and different
stimulation bursts are delivered during the stim-on phase. As described
above, all delivered stimulations have the same amplitude and the number
of bursts delivered depends on the duration of the respiratory event. For
this patient, in most cases, the respiratory episode is stopped during the first
stimulation burst. However, some over-stimulations were observed on this
patient, due to a lack of a correct detection of the end of the event for some
hypopnea episodes.
The first effect that can be noticed from the therapy in this responder
patient is that the duration of the apnea events is smaller during the stim-on
phase than during the stim-off phase. Also, due to these extended respira-
tory events, oxygen saturation (SaO2) (Figure 5-C) shows significant hypoxia
events (low oxygen saturation, some of them below 90%) during the stim-
off phase. These hypoxemia events are stopped by the stimulation therapy,
during the stim-on phase. Figure 5-D shows the instantaneous heart rate
(HR) during the same period. It can be noticed that tachycardia (high HR)
events, correlated to the apnea and hypoxia events and provoked by chemo
and baroreflex autonomic functions, are observed during the stim-off phase.
These tachycardia episodes are not present during the stim-on phase, during
which a normal and more stable respiratory sinus arrhythmia is observed.
Also, the mean HR during the whole stim-off episode was higher than the
mean HR of the stim-on episode. Finally, Figure 5-E shows the hypnogram
reconstructed from the manual annotations performed by the Core-lab. The
patient spent most of the time in this segment in REM and light sleep (LS)
stages. A number of micro-arousals (MA) are observed during the segment,
particularly at the end of each apnea episode during the stim-off phase and
after most kinesthetic stimulations, during the stim-on phase. One ”awake”
event was observed during the stim-on phase. A first qualitative analysis of
the sleep structure for this patient showed no major differences between the
stim-on and stim-off phases.
4.2.2. Partially responder patient
As previously defined, partially responder patients show a correct re-
sponse to the therapy during some parts of the night and a lesser or no re-
sponse in other parts of the night. This loss of response was often associated
with changes in posture or sleep stages during the night. Figure 6 depicts
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Figure 5: Cardiorespiratory response to kinesthetic stimulation of a responder patient. The
first 10 minutes correspond to the end of a non-stimulation (stim-off) phase and the next 10
minutes to a phase with triggered stimulation active (stim-on). The following signals are
displayed: A) nasal pressure (NP), B) signal driving the kinesthetic stimulator (Stim), C)
oxygen saturation (SaO2), D) instantaneous heart rate (HR), as detected from the ECG,
E) Hypnogram obtained from Core-lab annotations (MA = micro-arousal, A=Awake,
REM = Rapid eye movement, LS = light sleep, DS = deep sleep). This response shows
extended respiratory episodes accompanied by repeated hypoxia events during the stim-off
phase. Respiratory event durations are reduced and no hypoxia events (SaO2 <90%) are
observed during the stim-on phase. The stim-off phase is also characterized by significant
tachycardia events that are related to sympathetic activations due to prolonged apnea and
hypoxia. These tachycardia episodes are not observed during the stim-off phase, which
shows a physiological respiratory sinus arrhythmia.
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the same signals shown in Figure 5, but for a partially responder patient. A
correct response to the therapy is observed during the first minutes. The pa-
tient starts moving from a lateral to a dorsal position around minute 5. Once
in stable dorsal position (around minute 10), the response to the therapy is
strongly reduced, presenting, in particular, three respiratory episodes with
the maximum stimulation of 3 burst that failed to restore normal breathing.
As a consequence of this non-response, hypoxia episodes and tachycardia,
which were not observed during the first 10 minutes, appear after minute 10.
This example suggests that i) the actuator should be carefully fixed to the
skin of the patient and ii) stimulation parameters should be adjusted over
time in order to improve response.
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Figure 6: Cardiorespiratory response to kinesthetic stimulation of a partially responder
patient. The whole segment was acquired during a stim-on phase. The following signals are
displayed: A) nasal pressure (NP), B) signal driving the kinesthetic stimulator (Stim), C)
oxygen saturation (SaO2), D) instantaneous heart rate (HR), as detected from the ECG,
E) Hypnogram obtained from Core-lab annotations (MA = micro-arousal, A=Awake,
REM = Rapid eye movement, LS = light sleep, DS = deep sleep). In this example, the
patient responds correctly to the therapy during the first 9 minutes. At minute 6 the
patient starts moving and changes to dorsal position in minute 10. In this new position
(from minute 10), the effect of the therapy is reduced letting appear hypoxia and tachy-
bradycardia episodes.
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4.2.3. Non-responder patient
Figure 7 presents an example of a non-responder patient. Most of the
respiratory events in this example were treated by the maximum of 3 stim-
ulation bursts and normal respiration was not recovered during or just after
the end of the stimulation on each event. Even if the direct contribution
of the stimulation therapy in this case is not clear, apnea durations on this
segment are rather low, limiting the arrival of hypoxic events. Nevertheless,
marked increases in HR and micro-arousals are observed after each major
respiratory episode.
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Figure 7: Cardiorespiratory response to kinesthetic stimulation of a non-responder pa-
tient. The whole segment was acquired during a stim-on phase. The following signals are
displayed: A) nasal pressure (NP), B) signal driving the kinesthetic stimulator (Stim),
C) oxygen saturation (SaO2), D) instantaneous heart rate (HR), as detected from the ECG,
E) Hypnogram obtained from Core-lab annotations (MA = micro-arousal, A=Awake,
REM = Rapid eye movement, LS = light sleep, DS = deep sleep). In this example the
effect of the therapy is not clear. Although the respiratory events are of limited dura-
tion, most events are stimulated with the maximum of 3 stimulation bursts and normal
respiration is not recovered just after the stimulation.
15
5. Discussion
The PASITHEA v1 system worked satisfactorily during this first clinical
evaluation. Some technical difficulties were observed during the titration
phase, including Holter communication loss and the delivery of inappropriate
stimulation bursts. These problems were corrected before including the 34
patients of the second study phase. During the second study phase, the only
technical difficulties were related to a loss of continuity in the cable driving
the kinesthetic actuator and the physical uncoupling of the actuator from
the patients’ skin.
Concerning respiratory event detection, the initial method presented by
our team in [11], was improved and evaluated retrospectively. It should be
noticed that the proposed method has been developed for a real-time control
application, in order to activate the kinesthetic therapy. This real-time con-
straint means that the final detection has to be performed during the event
(before the event ends and normal breathing resumes), which is not the case
of most respiratory event detectors of the literature. Indeed, Berry et al.
reported an overall sensitivity of 58% and specificity of 98% for a detector
incorporated into their PAP system [14]. Contrary to our detector, they do
wait for the end of an event before counting it as an event (post-event detec-
tion), which presumably accounts for their better specificity. Using oxygen
desaturation and plethysmography as input signals, the detector proposed by
Amir et al. showed a global sensitivity of 81% and a PPV of 81.4% [15]. Yet
again, their detector counted events once terminated, since oxygen desatura-
tion can occur between 5 and 60 seconds after the end of a hypopnea/apnea.
Under the real-time constraints imposed by the PASITHEA project, the pro-
posed, improved real-time respiratory event detector provides a satisfactory
performance in terms of sensibility, specificity and, in particular, detection
delay.
This paper also shows original results concerning triggered kinesthetic
stimulation for the treatment of SAS. This first evaluation gave us valu-
able information on the feasibility of this therapy. Qualitative analysis of the
effect of the therapy on responder patients showed how the acute cardiorespi-
ratory consequences of respiratory events observed during the stim-off period
(prolonged apnea, hypoxia events associated with tachy- and bradycardia),
which may be deleterious to the patient in the long term, may be stopped or
significantly attenuated during the stim-on phase (see for example Fig. 5).
However, not all patients responded correctly to the therapy. We hypothesize
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that most of the non-responses observed on partially-responder patients may
be avoided by i) an earlier detection of respiratory episodes (such as that
obtained from the improved detector), leading to an earlier therapy; ii) ap-
propriate adaptation and personalization of the stimulation parameters and
iii) an improvement and dynamic estimation of the mechanical coupling be-
tween the actuator and the skin of the patient. Indeed, the control algorithm
used in this first study was rather simple (on-off control) and the stimulation
parameters (amplitude, burst duration, silent interval, maximum number of
bursts) were empirically fixed for all patients using the analysis of the first 12
patients of the clinical study. The objective of the second phase of the PA-
SITHEA project is to develop and evaluate such an advanced auto-adaptive
and personalized therapy delivery. The information acquired on this first
study and our recent works on algorithm-switching and model-based control
design are particularly valuable for these developments [16][17]. Finally, like
in any other therapy, it is expected that some patients will not respond to
the proposed stimulation approach. Further studies are directed to identify
the patients profile allowing for the optimization of patient selection.
6. Conclusions and future work
This paper presented an original ambulatory system for real-time detec-
tion and triggered therapy delivery, directed to patients suffering from SAS.
A first evaluation of this system on 46 severe obstructive SAS patients has
been performed, by assessing the ability of the system to correctly detect
respiratory events in real-time. This study also provided preliminary results
on the effect of the triggered kinesthetic stimulation therapy on these events.
Real-time respiratory event detection is clearly a challenge and the char-
acteristic trade-off between high sensitivity and high PPV is accentuated by
the real-time constraints. For the sake of the PASITHEA project, the aim
is to detect as many events as possible, and as early as possible, in order
to treat them before they can fully develop and result in desaturation or
micro-arousal. The improved detector presented in this paper was designed
for that purpose. The retrospective evaluation presented in this paper shows
that the improved detector provides a satisfactory performance, approaching
the level of performance of some post-event detectors.
Regarding the effects of kinesthetic stimulation on respiratory events, pre-
liminary results shown in this work are very encouraging. In order to better
characterize these effects on responder patients, a quantitative analysis is
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currently ongoing, by statistically comparing the duration and frequency of
respiratory events during stimulation or non-stimulation periods. The sleep
structure will also be quantitatively analyzed. Concerning non-responder
patients, two major improvements of the system are currently in develop-
ment: i) the replacement of the ”on-off” control method by a fully-adaptive
stimulation approach, based on multi-variate proportional-integral-derivative
(PID) controllers and ii) the integration of new sensors to estimate the level
of mechanical coupling of the actuator. Also, a better characterization the
patient population that may benefit from the proposed kinesthetic therapy
is being performed (e.g. patients without an autonomic dysfunction).
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